查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1988174

可卡因使用障礙市場：治療方法、適應症、支付方類型、醫療保健環境、通路和年齡層分類－2026年至2032年全球市場預測

Cocaine Use Disorder Market by Treatment Modality, Indication, Payer Type, Care Setting, Distribution Channel, Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年可卡因使用障礙市場價值 12.9 億美元，預計到 2025 年將成長至 13.7 億美元，年複合成長率為 6.25%，到 2032 年將達到 21 億美元。

主要市場統計數據
基準年 2024 12.9億美元
預計年份：2025年 13.7億美元
預測年份 2032 21億美元
複合年成長率 (%) 6.25%

了解可卡因使用障礙日益複雜的現狀及其對全球公共衛生系統和患者療效的深遠影響。

可卡因使用障礙是一個極其棘手的問題，它交織著臨床、社會和經濟等多個領域。隨著其流行程度的持續上升給醫療基礎設施帶來巨大壓力，相關人員必須直面這一障礙的複雜性。患者不僅要承受長期使用帶來的神經系統和心血管系統損害，還要承受波及家庭和社區的社會心理影響。在此背景下，採取綜合觀點至關重要：理解成癮的神經生物學基礎、行為介入措施的頻譜以及不斷發展的藥物治療方案。

可卡因使用障礙的治療和政策發生了變革性變化。

近年來，可卡因使用障礙的治療方法方法、法律規範和技術創新都發生了顯著變化。行為療法正日益普及，緊急管理和動機式訪談已被證明在維持戒斷方面具有持續的有效性。同時，將認知行為療法與新型藥物療法結合的綜合治療方案正在重新定義治療路徑。這些進展反映了整個行業更廣泛的趨勢，即針對個別神經生物學脆弱性和社會心理誘因進行個人化介入。

評估 2025 年美國關稅對獲得和負擔得起治療方案的累積影響。

2025年實施的新關稅措施對用於治療可卡因使用障礙的診斷試劑、藥物和治療設備的整個供應鏈都產生了影響。特定精神興奮劑化合物和先進監測設備的進口關稅提高，對製藥企業和診斷服務提供者都帶來了成本壓力。這些額外成本正在影響醫院和門診診所的籌資策略，迫使許多醫療機構重新評估其供應商合約並探索替代採購模式。

關鍵細分洞察揭示了治療方法、臨床環境、適應症、診斷、支付方概況和醫療保健提供者。

從治療方法角度分析市場可知，行為療法（包括認知行為療法、緊急管理和動機式訪談等框架）仍然是患者參與策略和復發預防的關鍵基礎。相較之下，旨在提供全面護理的多學科診所擴大採用綜合療法模式，無論是整合療法還是序貫療法。同時，藥物療法（包括選擇性血清素再回收抑制劑(SSRI)、血清素-正腎上腺素再回收抑制劑(SNRI) 和新型精神興奮劑製劑）正成為重症患者的重要輔助性治療。

強調全球醫療保健基礎設施中可卡因使用障礙治療和政策應對措施方面存在的顯著區域差異。

世界各地在可卡因使用障礙干預措施的採納和實施方面存在顯著的區域差異。

在美洲，強力的宣傳宣傳活動和對門診網路的巨額投資正在推動緊急管理和綜合療法計畫的廣泛應用。區域法規環境支持遠端醫療的保險覆蓋，從而改善了農村地區獲得認知行為療法的機會。

介紹引領可卡因使用障礙治療未來發展的主要企業透過創新、合作和服務拓展來實現這一目標。

主要企業正繼續與學術機構和生物技術創新者建立策略合作夥伴關係，以加速開發旨在調節多巴胺路徑並降低復發風險的新型藥物療法。這些合作正在催生早期分子藥物，這些藥物目前正在進行臨床評估，以檢驗其在治療慢性可卡因成癮的療效和安全性。

為產業領導者提供切實可行的建議，以推動治療效果的改善、營運效率的最佳化和協作成長。

鼓勵領導者採用精準醫療方法，利用心血管和神經系統檢查中識別出的診斷生物標記物，制定個人化的藥物治療方案。這種分層策略可以提高療效並減少不利事件。此外，應藉助安全的遠端醫療平台，支援門診診所緊急管理方案的推廣，以確保病患監測和遠距諮詢。

強調多源資料整合、嚴格檢驗和分析透明性的綜合調查方法。

本研究採用混合方法，將對關鍵臨床醫生、保險公司和政策專家的定性訪談與同行評審期刊和政府出版刊物的二手研究相結合。臨床結果數據來自多中心合作研究和匿名化的患者登記數據，確保涵蓋不同的人口統計和地理區域。市場趨勢分析結合了自上而下的政策分析和自下而上的服務利用數據，並透過交叉引用採購記錄和支付方報銷資料庫來確保數據的一致性。

可卡因使用障礙治療的市場動態、臨床創新和策略挑戰概述

可卡因使用障礙治療領域的發展格局呈現出臨床創新、政策改革和技術進步交會融合的趨勢。行為療法和聯合療法模式不斷調整，並得到針對神經生物學路徑的新型藥物療法的支持。監管變革，包括費用調整和遠端醫療的擴展，為價值鏈上的所有相關人員帶來了挑戰和機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：可卡因使用障礙治療方法市場

  • 行為療法
    • 認知行為療法
    • 緊急管理
    • 動機式訪談
  • 輔助和輔助性治療
    • 正念和體育活動項目
    • 營養和補充計劃
  • 藥物治療
    • 抗憂鬱症
      • 選擇性血清素再回收抑制劑
      • 血清素-正腎上腺素再回收抑制劑
    • 精神興奮劑
    • 抗精神病藥物
    • 抗驚厥藥物
  • 使用醫療設備進行治療
    • 非侵入性神經調控
    • 侵入性神經調控

第9章：可卡因使用障礙市場：依適應症分類

  • 急性
  • 慢性的

第10章：按支付方類型分類的可卡因使用障礙市場

  • 自費
  • 私人保險
  • 公共資金

第11章：醫療機構可卡因使用障礙市場

  • 醫院項目
  • 社區健康中心
  • 專門的成癮診所
  • 復健中心

第12章：可卡因使用障礙市場：依通路分類

  • 藥局
  • 數位健康平台

第13章：可卡因使用障礙市場：依年齡層別分類

  • 18歲以下的青少年
  • 成年人（18-45歲）

第14章：可卡因使用障礙市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：可卡因使用障礙市場：依群體分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：可卡因使用障礙市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國可卡因使用障礙市場

第18章：中國可卡因使用障礙市場

第19章 競爭情勢

  • 2024年市場集中度分析
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2024 年
  • 2024年產品系列分析
  • 基準分析，2024 年
  • Addex Therapeutics
  • Alkermes PLC
  • Catalyst Pharmaceutical Partners, Inc.
  • Clearmind Medicine Inc.
  • Embera NeuroTherapeutics, Inc.
  • Novartis AG
  • Omeros Corporation
  • SciSparc Ltd.
  • STALICLA SA
  • Tempero Bio, Inc.
Product Code: MRR-F97DD5A7E128

The Cocaine Use Disorder Market was valued at USD 1.29 billion in 2024 and is projected to grow to USD 1.37 billion in 2025, with a CAGR of 6.25%, reaching USD 2.10 billion by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.29 billion
Estimated Year [2025] USD 1.37 billion
Forecast Year [2032] USD 2.10 billion
CAGR (%) 6.25%

Understanding the Growing Complexity of Cocaine Use Disorder and Its Far-Reaching Implications on Public Health Systems and Patient Outcomes Globally

Cocaine use disorder presents a formidable challenge that intersects clinical, social, and economic spheres. As prevalence continues to exert pressure on healthcare infrastructures, stakeholders must confront the multifaceted nature of this condition. Patients grapple not only with the neurological and cardiovascular consequences of chronic use but also with the psychosocial ramifications that ripple through families and communities. In this context, an integrated perspective is critical: understanding the neurobiological underpinnings of addiction, the spectrum of behavioral interventions, and the evolving pharmacotherapeutic options.

Moreover, public health systems are tasked with designing policies that balance prevention, harm reduction, and treatment accessibility. Simultaneously, private providers strive to innovate treatment modalities that can adapt to diverse patient profiles. Consequently, this section sets the stage by outlining the intricate interplay between patient needs, clinical advancements, and policy imperatives. By clarifying the core complexities and drivers of cocaine use disorder, readers are positioned to appreciate the subsequent analysis of market dynamics, regulatory impacts, segmentation nuances, regional variations, and strategic recommendations.

Transformative Shifts in the Landscape of Cocaine Use Disorder Treatment and Policy

Recent years have witnessed seismic shifts in how cocaine use disorder is addressed, spanning treatment modalities, regulatory frameworks, and technological innovations. Behavioral therapy approaches have gained momentum, with contingency management and motivational interviewing demonstrating sustained efficacy in promoting abstinence. Concurrently, integrated treatment programs that combine cognitive behavioral therapy with emerging pharmacotherapeutic agents are redefining care pathways. These advancements reflect a broader industry trend toward personalized interventions designed to target individual neurobiological vulnerabilities and psychosocial triggers.

Policy landscapes have evolved in tandem. Shifting public sentiment and data-driven advocacy have spurred decriminalization efforts in select jurisdictions, while federal agencies recalibrate funding priorities to emphasize prevention and early intervention. At the same time, the expansion of telehealth platforms has reduced geographic treatment gaps, enabling remote behavioral therapy sessions and electronic prescription monitoring for pharmacotherapy. Taken together, these transformative shifts underscore the dynamic convergence of clinical innovation, policy reform, and digital health solutions that are reshaping the response to cocaine use disorder across the continuum of care.

Evaluating the Cumulative Impact of United States Tariffs in 2025 on Access and Affordability of Treatment Solutions

The enactment of new tariff measures in 2025 has reverberated throughout the supply chains of diagnostics, medications, and therapeutic equipment utilized in cocaine use disorder treatment. Increased import duties on specialized psychostimulant compounds and advanced monitoring devices have triggered cost pressures for pharmaceutical manufacturers and diagnostic service providers alike. These added expenses have, in turn, influenced procurement strategies within hospitals and outpatient clinics, compelling many institutions to reevaluate vendor contracts and explore alternative sourcing models.

In response, healthcare systems have intensified dialogues with policymakers to advocate for tariff relief on essential care components. Some regional coalitions have secured exemptions for equipment integral to urine toxicology screening and cardiovascular monitoring, thereby preserving critical diagnostic capabilities. Nonetheless, smaller community clinics remain vulnerable to cost escalation, which may hinder their capacity to offer comprehensive services. As this section illustrates, the 2025 tariff landscape demands strategic adaptation across the value chain, affecting everything from raw material sourcing to patient-level access and coverage.

Key Segmentation Insights to Illuminate Distinct Treatment Modalities, Settings, Indications, Diagnostics, Payer Profiles, and Care Providers

Analyzing the market through the lens of treatment modality reveals that behavioral therapy, with its cognitive behavioral therapy, contingency management, and motivational interviewing frameworks, continues to anchor patient engagement strategies and relapse prevention. By contrast, combined therapy models-whether integrated or sequential-are gaining adoption among multidisciplinary clinics striving for holistic care. Meanwhile, pharmacotherapy, spanning selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and novel psychostimulant formulations, is emerging as a critical adjunct in severe cases.

Treatment settings range from inpatient services, which encompass both detoxification units and residential rehabilitation facilities, to outpatient programs that facilitate ongoing support within community and private clinic environments. Patient journeys differ based on indication, with acute interventions focused on immediate detoxification protocols and chronic care pathways emphasizing long-term maintenance and comorbidity management. Diagnostic tests play a pivotal role in tailoring interventions: cardiovascular assessments detect long-term strain, neurologic examinations monitor cognitive deficits, and urine toxicology screens verify adherence and identify polysubstance use.

Funding sources also shape treatment accessibility. Out-of-pocket payers confront direct costs that influence treatment duration, whereas private insurers negotiate coverage tiers and prior authorization processes. Public funding mechanisms bridge gaps for underserved populations, yet they are susceptible to policy fluctuations. Finally, provider types-from community and private clinics to general and psychiatric hospitals and both public and private rehabilitation centers-exhibit distinct capacities to deliver specialized programs. Each segment contributes a layer of nuance to understanding how services align with patient needs and systemic constraints.

Highlighting Critical Regional Variations in Cocaine Use Disorder Treatment Adoption and Policy Responses Across Global Territories and Healthcare Infrastructures

Critical Regional Variations Shaping the Adoption and Implementation of Cocaine Use Disorder Interventions Across Global Territories

Within the Americas, robust public awareness campaigns and significant investments in outpatient clinic networks have driven broader adoption of contingency management and integrated therapy programs. This region's regulatory environment supports telehealth reimbursement, enhancing access to cognitive behavioral therapy in rural areas.

In Europe, Middle East & Africa, diverse healthcare infrastructures reflect a patchwork of public funding models. Western European countries benefit from established reimbursement pathways for pharmacotherapy, while emerging markets in the Middle East grapple with workforce shortages in psychiatric hospitals. In Africa, public rehabilitation centers face resource constraints, intensifying reliance on community clinics and nonprofit initiatives.

Across Asia-Pacific, rapid expansion of private clinics and increasing public insurance coverage have catalyzed growth in both inpatient detoxification services and outpatient combined therapies. Japan's stringent diagnostic protocols for cardiovascular and neurologic examinations ensure early detection, whereas Australia's emphasis on motivational interviewing leverages telemedicine platforms to reach remote populations. These regional insights underscore how policy frameworks, funding mechanisms, and cultural attitudes converge to shape the delivery and uptake of treatment modalities.

Profiling Leading Companies Shaping the Future of Cocaine Use Disorder Treatment Through Innovation, Collaboration, and Service Expansion

Major players continue to forge strategic alliances with academic institutions and biotech innovators to accelerate the development of novel pharmacotherapeutics aimed at modulating dopamine pathways and reducing relapse risk. These collaborations have yielded early-stage molecules currently under clinical evaluation for efficacy and safety in chronic cocaine dependence.

In parallel, prominent behavioral health providers are scaling digital therapy platforms that integrate real-time biometric feedback with contingency management protocols. By deploying AI-driven adherence monitoring, these companies are enhancing patient engagement and optimizing therapist interventions. Meanwhile, diagnostic solution leaders are refining point-of-care urine toxicology devices, delivering faster turnaround times and improved accuracy, which supports more agile treatment adjustments.

Service-oriented organizations, including rehabilitation centers across both public and private sectors, are expanding footprint through franchising models and strategic acquisitions. This trend is particularly notable in regions with underpenetrated outpatient services, where local partnerships facilitate knowledge transfer and capacity building. Collectively, these company initiatives exemplify a commitment to comprehensive care models that span prevention, acute intervention, and long-term recovery pathways.

Actionable Recommendations for Industry Leaders to Enhance Treatment Outcomes, Optimize Operational Efficiency, and Drive Collaborative Growth

Leaders are encouraged to integrate precision medicine approaches by leveraging diagnostic biomarkers identified through cardiovascular and neurologic examinations to tailor pharmacotherapy regimens. This stratified strategy can improve efficacy and reduce adverse events. Furthermore, the expansion of contingency management programs within outpatient clinics should be supported by secure telehealth platforms that ensure consistent patient monitoring and remote counseling.

Operationally, organizations should explore co-development partnerships between private rehabilitation centers and psychiatric hospitals to streamline referral pathways and share best practices. Simultaneously, engaging payer stakeholders-both in public funding bodies and private insurers-through outcomes-based contracting can align reimbursement models with clinical performance metrics, incentivizing value-driven care.

Finally, investing in workforce development initiatives that train community and private clinic personnel in motivational interviewing and integrated therapy protocols will strengthen service delivery in underserved areas. By adopting these recommendations, industry leaders can elevate patient outcomes, foster cost efficiencies, and establish robust frameworks for sustained innovation.

Comprehensive Research Methodology Emphasizing Multisource Data Integration, Rigorous Validation, and Analytical Transparency

This study employs a mixed-methods approach, integrating primary qualitative interviews with leading clinicians, payers, and policy experts alongside secondary research from peer-reviewed journals and government publications. Data on clinical outcomes were aggregated from multicenter studies and anonymized patient registries, ensuring representation across diverse demographic and geographic segments. Market trends were analyzed through a combination of top-down policy analyses and bottom-up service utilization data, with triangulation achieved via cross-referencing procurement records and payer reimbursement databases.

Quantitative modeling techniques were applied to evaluate cost structures and resource allocation across inpatient and outpatient settings. Scenario analysis assessed the impact of tariff changes on supply chains and care delivery. All data inputs underwent rigorous validation through expert panels and sensitivity testing, guaranteeing methodological robustness and reproducibility. The integrated analytical framework ensures that findings reflect both macro-level industry dynamics and micro-level operational realities, providing stakeholders with a transparent and reliable basis for strategic decision-making.

Concluding Reflections on Market Dynamics, Clinical Innovations, and Strategic Imperatives for Cocaine Use Disorder Treatment

The evolving landscape of cocaine use disorder treatment is characterized by a convergence of clinical innovation, policy reform, and technological advancement. Behavioral and combined therapy models continue to adapt, bolstered by emerging pharmacotherapies that target neurobiological pathways. Regulatory shifts, including tariff adjustments and telehealth expansions, have introduced both challenges and opportunities for stakeholders across the value chain.

Through a detailed segmentation lens, this report underscores the importance of aligning treatment modalities with patient indications, funding mechanisms, and provider capabilities. Regional insights reveal that policy frameworks and infrastructure investments directly influence service adoption and equity of access. Company profiles highlight a dynamic ecosystem of collaborations and service expansions, while recommended strategies offer a roadmap for enhancing outcomes and operational resilience.

As the industry moves forward, stakeholders must remain vigilant to regulatory changes, embrace data-driven personalization of care, and cultivate cross-sector partnerships. This integrated approach will be essential in addressing the complex needs of individuals affected by cocaine use disorder and in driving sustainable progress across the continuum of treatment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cocaine Use Disorder Market, by Treatment Modality

  • 8.1. Behavioral Therapy
    • 8.1.1. Cognitive Behavioral Therapy
    • 8.1.2. Contingency Management
    • 8.1.3. Motivational Interviewing
  • 8.2. Complementary & Adjunctive Therapies
    • 8.2.1. Mindfulness & Physical Activity Programs
    • 8.2.2. Nutritional & Supplement Programs
  • 8.3. Pharmacotherapy
    • 8.3.1. Antidepressants
      • 8.3.1.1. Selective Serotonin Reuptake Inhibitors
      • 8.3.1.2. Serotonin-Norepinephrine Reuptake Inhibitors
    • 8.3.2. Psychostimulants
    • 8.3.3. Antipsychotics
    • 8.3.4. Anticonvulsants
  • 8.4. Device-Based Therapies
    • 8.4.1. Non-Invasive Neuromodulation
    • 8.4.2. Invasive Neuromodulation

9. Cocaine Use Disorder Market, by Indication

  • 9.1. Acute
  • 9.2. Chronic

10. Cocaine Use Disorder Market, by Payer Type

  • 10.1. Self-Funded
  • 10.2. Private Coverage
  • 10.3. Public Funding

11. Cocaine Use Disorder Market, by Care Setting

  • 11.1. Hospital-Based Programs
  • 11.2. Community Health Centers
  • 11.3. Specialty Addiction Clinics
  • 11.4. Rehabilitation Centers

12. Cocaine Use Disorder Market, by Distribution Channel

  • 12.1. Pharmacies
  • 12.2. Digital Health Platforms

13. Cocaine Use Disorder Market, by Age Group

  • 13.1. Adolescents (< 18)
  • 13.2. Adults (18-45)

14. Cocaine Use Disorder Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cocaine Use Disorder Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cocaine Use Disorder Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Cocaine Use Disorder Market

18. China Cocaine Use Disorder Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2024
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2024
  • 19.3. Product Portfolio Analysis, 2024
  • 19.4. Benchmarking Analysis, 2024
  • 19.5. Addex Therapeutics
  • 19.6. Alkermes PLC
  • 19.7. Catalyst Pharmaceutical Partners, Inc.
  • 19.8. Clearmind Medicine Inc.
  • 19.9. Embera NeuroTherapeutics, Inc.
  • 19.10. Novartis AG
  • 19.11. Omeros Corporation
  • 19.12. SciSparc Ltd.
  • 19.13. STALICLA SA
  • 19.14. Tempero Bio, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COCAINE USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COCAINE USE DISORDER MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL COCAINE USE DISORDER MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY PAYER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY CARE SETTING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES COCAINE USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA COCAINE USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COCAINE USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY CONTINGENCY MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY CONTINGENCY MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY CONTINGENCY MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY MOTIVATIONAL INTERVIEWING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY MOTIVATIONAL INTERVIEWING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY MOTIVATIONAL INTERVIEWING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY COMPLEMENTARY & ADJUNCTIVE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY COMPLEMENTARY & ADJUNCTIVE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY COMPLEMENTARY & ADJUNCTIVE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY COMPLEMENTARY & ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY MINDFULNESS & PHYSICAL ACTIVITY PROGRAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY MINDFULNESS & PHYSICAL ACTIVITY PROGRAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY MINDFULNESS & PHYSICAL ACTIVITY PROGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY NUTRITIONAL & SUPPLEMENT PROGRAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY NUTRITIONAL & SUPPLEMENT PROGRAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY NUTRITIONAL & SUPPLEMENT PROGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY PSYCHOSTIMULANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY PSYCHOSTIMULANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY PSYCHOSTIMULANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY ANTIPSYCHOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY ANTIPSYCHOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY ANTIPSYCHOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY DEVICE-BASED THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY DEVICE-BASED THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY DEVICE-BASED THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY DEVICE-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY NON-INVASIVE NEUROMODULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY NON-INVASIVE NEUROMODULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY NON-INVASIVE NEUROMODULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY INVASIVE NEUROMODULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY INVASIVE NEUROMODULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY INVASIVE NEUROMODULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY ACUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY ACUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY ACUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY CHRONIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY CHRONIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY CHRONIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY SELF-FUNDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY SELF-FUNDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY SELF-FUNDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY PRIVATE COVERAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY PRIVATE COVERAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY PRIVATE COVERAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY PUBLIC FUNDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY PUBLIC FUNDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY PUBLIC FUNDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY HOSPITAL-BASED PROGRAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY HOSPITAL-BASED PROGRAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY HOSPITAL-BASED PROGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY SPECIALTY ADDICTION CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY SPECIALTY ADDICTION CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY SPECIALTY ADDICTION CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY DIGITAL HEALTH PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY DIGITAL HEALTH PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY DIGITAL HEALTH PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY ADOLESCENTS (< 18), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY ADOLESCENTS (< 18), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY ADOLESCENTS (< 18), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY ADULTS (18-45), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY ADULTS (18-45), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY ADULTS (18-45), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS COCAINE USE DISORDER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS COCAINE USE DISORDER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS COCAINE USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS COCAINE USE DISORDER MARKET SIZE, BY COMPLEMENTARY & ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS COCAINE USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS COCAINE USE DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS COCAINE USE DISORDER MARKET SIZE, BY DEVICE-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS COCAINE USE DISORDER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS COCAINE USE DISORDER MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS COCAINE USE DISORDER MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS COCAINE USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS COCAINE USE DISORDER MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA COCAINE USE DISORDER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA COCAINE USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA COCAINE USE DISORDER MARKET SIZE, BY COMPLEMENTARY & ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA COCAINE USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA COCAINE USE DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA COCAINE USE DISORDER MARKET SIZE, BY DEVICE-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA COCAINE USE DISORDER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA COCAINE USE DISORDER MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA COCAINE USE DISORDER MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA COCAINE USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA COCAINE USE DISORDER MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA COCAINE USE DISORDER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA COCAINE USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA COCAINE USE DISORDER MARKET SIZE, BY COMPLEMENTARY & ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA COCAINE USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA COCAINE USE DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA COCAINE USE DISORDER MARKET SIZE, BY DEVICE-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA COCAINE USE DISORDER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA COCAINE USE DISORDER MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA COCAINE USE DISORDER MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA COCAINE USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA COCAINE USE DISORDER MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA COCAINE USE DISORDER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA COCAINE USE DISORDER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA COCAINE USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA COCAINE USE DISORDER MARKET SIZE, BY COMPLEMENTARY & ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA COCAINE USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA COCAINE USE DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA COCAINE USE DISORDER MARKET SIZE, BY DEVICE-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA COCAINE USE DISORDER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA COCAINE USE DISORDER MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA COCAINE USE DISORDER MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA COCAINE USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA COCAINE USE DISORDER MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE COCAINE USE DISORDER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE COCAINE USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE COCAINE USE DISORDER MARKET SIZE, BY COMPLEMENTARY & ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE COCAINE USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE COCAINE USE DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE COCAINE USE DISORDER MARKET SIZE, BY DEVICE-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE COCAINE USE DISORDER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE COCAINE USE DISORDER MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE COCAINE USE DISORDER MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE COCAINE USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE COCAINE USE DISORDER MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST COCAINE USE DISORDER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST COCAINE USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST COCAINE USE DISORDER MARKET SIZE, BY COMPLEMENTARY & ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST COCAINE USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST COCAINE USE DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST COCAINE USE DISORDER MARKET SIZE, BY DEVICE-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST COCAINE USE DISORDER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST COCAINE USE DISORDER MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST COCAINE USE DISORDER MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST COCAINE USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST COCAINE USE DISORDER MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA COCAINE USE DISORDER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA COCAINE USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA COCAINE USE DISORDER MARKET SIZE, BY COMPLEMENTARY & ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA COCAINE USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA COCAINE USE DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA COCAINE USE DISORDER MARKET SIZE, BY DEVICE-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA COCAINE USE DISORDER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA COCAINE USE DISORDER MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA COCAINE USE DISORDER MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA COCAINE USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA COCAINE USE DISORDER MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC COCAINE USE DISORDER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC COCAINE USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC COCAINE USE DISORDER MARKET SIZE, BY COMPLEMENTARY & ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC COCAINE USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC COCAINE USE DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC COCAINE USE DISORDER MARKET SIZE, BY DEVICE-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC COCAINE USE DISORDER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC COCAINE USE DISORDER MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC COCAINE USE DISORDER MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC COCAINE USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC COCAINE USE DISORDER MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN COCAINE USE DISORDER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN COCAINE USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN COCAINE USE DISORDER MARKET SIZE, BY COMPLEMENTARY & ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN COCAINE USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN COCAINE USE DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN COCAINE USE DISORDER MARKET SIZE, BY DEVICE-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN COCAINE USE DISORDER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN COCAINE USE DISORDER MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN COCAINE USE DISORDER MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN COCAINE USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN COCAINE USE DISORDER MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. GCC COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. GCC COCAINE USE DISORDER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 215. GCC COCAINE USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. GCC COCAINE USE DISORDER MARKET SIZE, BY COMPLEMENTARY & ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 217. GCC COCAINE USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. GCC COCAINE USE DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 219. GCC COCAINE USE DISORDER MARKET SIZE, BY DEVICE-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 220. GCC COCAINE USE DISORDER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 221. GCC COCAINE USE DISORDER MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. GCC COCAINE USE DISORDER MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 223. GCC COCAINE USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. GCC COCAINE USE DISORDER MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION COCAINE USE DISORDER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION COCAINE USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION COCAINE USE DISORDER MARKET SIZE, BY COMPLEMENTARY & ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION COCAINE USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION COCAINE USE DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION COCAINE USE DISORDER MARKET SIZE, BY DEVICE-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION COCAINE USE DISORDER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION COCAINE USE DISORDER MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION COCAINE USE DISORDER MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION COCAINE USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION COCAINE USE DISORDER MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS COCAINE USE DISORDER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS COCAINE USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS COCAINE USE DISORDER MARKET SIZE, BY COMPLEMENTARY & ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS COCAINE USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS COCAINE USE DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS COCAINE USE DISORDER MARKET SIZE, BY DEVICE-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS COCAINE USE DISORDER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS COCAINE USE DISORDER MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS COCAINE USE DISORDER MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS COCAINE USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS COCAINE USE DISORDER MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. G7 COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. G7 COCAINE USE DISORDER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 251. G7 COCAINE USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. G7 COCAINE USE DISORDER MARKET SIZE, BY COMPLEMENTARY & ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 253. G7 COCAINE USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 254. G7 COCAINE USE DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 255. G7 COCAINE USE DISORDER MARKET SIZE, BY DEVICE-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 256. G7 COCAINE USE DISORDER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 257. G7 COCAINE USE DISORDER MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. G7 COCAINE USE DISORDER MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 259. G7 COCAINE USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. G7 COCAINE USE DISORDER MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 261. NATO COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. NATO COCAINE USE DISORDER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 263. NATO COCAINE USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 264. NATO COCAINE USE DISORDER MARKET SIZE, BY COMPLEMENTARY & ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 265. NATO COCAINE USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. NATO COCAINE USE DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 267. NATO COCAINE USE DISORDER MARKET SIZE, BY DEVICE-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 268. NATO COCAINE USE DISORDER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 269. NATO COCAINE USE DISORDER MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. NATO COCAINE USE DISORDER MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 271. NATO COCAINE USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. NATO COCAINE USE DISORDER MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES COCAINE USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES COCAINE USE DISORDER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES COCAINE USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES COCAINE USE DISORDER MARKET SIZE, BY COMPLEMENTARY & ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES COCAINE USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES COCAINE USE DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES COCAINE USE DISORDER MARKET SIZE, BY DEVICE-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES COCAINE USE DISORDER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES COCAINE USE DISORDER MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES COCAINE USE DISORDER MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES COCAINE USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES COCAINE USE DISORDER MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA COCAINE USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA COCAINE USE DISORDER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA COCAINE USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA COCAINE USE DISORDER MARKET SIZE, BY COMPLEMENTARY & ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA COCAINE USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA COCAINE USE DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA COCAINE USE DISORDER MARKET SIZE, BY DEVICE-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA COCAINE USE DISORDER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA COCAINE USE DISORDER MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA COCAINE USE DISORDER MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA COCAINE USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA COCAINE USE DISORDER MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)